Closed: 15 November 2017
The Australian Technical Advisory Group on Immunisation (ATAGI) is consulting with stakeholders on proposed changes to the HPV vaccination recommendations for inclusion in the Australian Immunisation Handbook.
The Therapeutic Goods Administration registered Gardasil 9 as a 2-dose schedule in June 2017 and the Pharmaceutical Benefits Advisory Committee recommended in July that it be provided through the National Immunisation Program (NIP). The vaccine is expected to be available in Australia from 2018. These changes have prompted a review of the HPV recommendations in the Australian Immunisation Handbook, and the proposed changes reflect the current best clinical practice for prevention of HPV infection and associated disease.
The new draft recommendations and the rationale for the changes are outlined in the public consultation document.
ATAGI sought comments on the following:
- Are there additional potential benefits, risks or unintended consequences which could arise from the proposed changes to the use of HPV vaccines, not already outlined and how likely are they to occur?
- Are there additional clinical or implementation considerations which need to be outlined?
- Any further comments you may have.